No Data
Would RemeGen (HKG:9995) Be Better Off With Less Debt?
REMEGEN (09995): The invalidation of some unvested restricted stocks granted under the 2022 A-share restricted stock incentive plan.
REMEGEN (09995) released an announcement based on the "Management Measures for Stock-based Incentive of Listed Companies" and "2022 A-shares Limitation..."
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
RemeGen Co. Ltd. to Strengthen Leadership With New Director
RemeGen Co. Ltd. Announces 2025 Extraordinary Meeting
REMEGEN (09995.HK): Huang Guobin has been nominated as an independent non-executive Director candidate.
Gelonghui, December 23丨REMEGEN (09995.HK) announced that at the Board of Directors meeting to be held on December 23, 2024, Huang Guobin has been nominated as a candidate for the company's independent non-executive director.
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
No Data
